-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Finance App News, Fosun Pharmaceutical (02196.HK) announced that recently, the company's holding subsidiary, Chengdu Xingrui Jingxuan Biotechnology Co., Ltd. received clinical trial approval from the State Drug Administration to approve [18F] F-SR031 injections for use in positron emission tomography (PET) imaging of fibroblast-activating protein (FAP) positive lesions in patients with solid tumors. Xingrui Jingxuan plans to conduct phase I clinical research on this drug in China when conditions are met.

Zhitongcaijing·11/16/2026 10:17:22
Listen to the news
Zhitong Finance App News, Fosun Pharmaceutical (02196.HK) announced that recently, the company's holding subsidiary, Chengdu Xingrui Jingxuan Biotechnology Co., Ltd. received clinical trial approval from the State Drug Administration to approve [18F] F-SR031 injections for use in positron emission tomography (PET) imaging of fibroblast-activating protein (FAP) positive lesions in patients with solid tumors. Xingrui Jingxuan plans to conduct phase I clinical research on this drug in China when conditions are met.